| 원저 / 만성 간질환과 간세포암종 환자에서 Basic Fibroblast Growth Factor와 Vascular Endothelial Growth Factor의 혈청 농도 ( Implications of Serum Levels of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Chronic Liver Diseases and |
|
|
| Implications of Serum Levels of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Chronic Liver Diseases and Hepatocellular Carcinoma |
| Sung Jae Yoo, M.D, Sung Moon Jung, M.D, Jong Gwang Kim, M.D, Jin Ok Lee, M.D,
Yong Whan Song, M.D, Chul Ju Han, M.D, Sook-Hyang Jung, M.D, You Cheoul Kim, M.D,
Chang-Min Kim, M.D, Jhin Oh Lee, M.D, Young Joon Hong, M.D* and Seok Il Hong, M.D* |
| Department of Internal Medicine and Clinical Pathology* Korea Cancer Center Hosp ital, Seoul, Korea |
|
|
|
|
| ABSTRACT |
|
Background/Aims
Angiogenesis occurs in response to tissue damage, and is of vital importance for tumor growth and metastasis. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are potent angiogenic factors, and have been suggested to be useful diagnostic markers in certain hypervascular tumors. However, little is known of serum bFGF and VEGF in patients with hepatocellular carcinoma (HCC). We attempted to measure serum bFGF and VEGF in patients with chronic liver diseases (CLD) and HCC to assess their pathogenetic role and usability as tumor markers. Methods: Serum bFGF and VEGF were measured in 8 patients with chronic hepatitis (CH), 15 patients with liver cirrhosis (LC), and 49 patients with HCC. bFGF was measured in 33, and VEGF was measured in 50, healthy blood donors. Results: Serum bFGF was 3.8±1.9, 2.0±1.4, 4.2±6.0, 17.4±30.0 pg/mL in normal control, CH, LC, HCC, respectively. The serum bFGF level was significantly increased in patients with HCC when compared with normal control or patients with CLD. No difference, however, was observed in serum VEGF levels among the four groups. The serum levels of bFGF and VEGF were not significantly different in patients with HCC according to tumor type, size and stage. Serum bFGF showed good sensitivity (90%), specificity (87%), and positive predictive value (94%) in differentiating patients with HCC from those with CLD at the cut-off value of 4.6 pg/mL. Conclusions: bFGF might play a role in the growth of HCC and its serum level might be used as a tumor marker. On the other hand, serum VEGF does not seem to be an adequate tumor marker.(Korean J Hepatol 2001;7:47-54) |
| KeyWords:
Chronic liver disease, Neoplasm/ Liv er/Hepatocellular carcinoma, bFGF , VEGF , Angiogenesis |
|
|
PDF Links
Full text via DOI
Download Citation
